Skip to content
value.today

Paulex Bio Inc.

🇺🇸 La Jolla, California, USAPharmaceuticalsFounded 2023
Total raised
$19 M
1 round on record
Latest round
$19 M
Nov 2025
First round on record
Nov 2025
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Paulex Bio Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$19 MNo. 1$10 to $50 million

Paulex Bio Inc.: Raise no. 1, Nov 2025

Investors in this round

163 investors had bought by the notice of Dec 18, 2025: 163 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $23 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,575,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sanjuan Miguel · Executive Officer, Director · Chief Executive Officer
  • Edgardo Rayo · Director
  • Francisco Leon · Director
  • Mohammad Hayat · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MDB Capital (CRD 000042677) · Addison, TexasSold in all US states, and outside the US

Remarks in the notice

  • On fees: “Sales commission estimate based on assumption of maximum offering amount sold.”
  • On the use of proceeds: “Proceeds to be used for working capital and general corporate purposes.”

Signed by Miguel Sanjuan, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 18, 2025. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Paulex Bio Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2025

That is all the official record says: Paulex Bio Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Paulex Bio Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 163 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Paulex Bio Inc.
NameRoleNamed in
Sanjuan MiguelChief Executive OfficerDec 2025
Edgardo RayoDirectorDec 2025
Francisco LeonDirectorDec 2025
Mohammad HayatDirectorDec 2025
Sanjuan MiguelChief Executive OfficerDec 2025